Drug discovery positron emission tomography

The availability of effective SERT and DAT radioligands for positron emission tomography (PET) has led to studies in which transporter occupancy of drugs can be determined in a non-invasive manner [26]. Similar studies to determine NET occupancy using PET have been hindered due to the lack of availability of a suitable NET ligand. Progress towards the discovery of NET... 

One of the modem ways of CNS disorders diagnostics depends on the development of new radiolabeled NKl receptor antagonists. Some examples of fluorine-18 labeling compounds are known [171,172], effective radioligands for imaging brain neurokinin type-1 (NKl) receptors in clinical research and drug discovery with positron emission tomography, like [ F]SPA-RQ 198. 

Quantitative imaging in drug discovery using positron emission tomography... 

Piel, M., Vemaleken, I., Rosch, R, 2014. Positron emission tomography in CNS drug discovery and drug monitoring. J. Med. Chem. 57, 9232-9258. 

---